vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Mayville Engineering Company, Inc. (MEC). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $134.3M, roughly 1.4× Mayville Engineering Company, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -3.2%, a 16.6% gap on every dollar of revenue. On growth, Mayville Engineering Company, Inc. posted the faster year-over-year revenue change (10.7% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $10.2M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -8.8%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Mayville Engineering Company, Inc. is a U.S.-headquartered leading manufacturer of metal components, fabricated assemblies, and custom engineered solutions. It serves OEM clients across agriculture, construction, transportation, defense, and power sports markets, offering end-to-end services from prototyping to high-volume production for North America.
AMPH vs MEC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $134.3M |
| Net Profit | $24.4M | $-4.4M |
| Gross Margin | 46.8% | 6.8% |
| Operating Margin | 19.4% | -4.1% |
| Net Margin | 13.3% | -3.2% |
| Revenue YoY | -1.8% | 10.7% |
| Net Profit YoY | -35.7% | -127.3% |
| EPS (diluted) | $0.51 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $134.3M | ||
| Q3 25 | $191.8M | $144.3M | ||
| Q2 25 | $174.4M | $132.3M | ||
| Q1 25 | $170.5M | $135.6M | ||
| Q4 24 | $186.5M | $121.3M | ||
| Q3 24 | $191.2M | $135.4M | ||
| Q2 24 | $182.4M | $163.6M | ||
| Q1 24 | $171.8M | $161.3M |
| Q4 25 | $24.4M | $-4.4M | ||
| Q3 25 | $17.4M | $-2.7M | ||
| Q2 25 | $31.0M | $-1.1M | ||
| Q1 25 | $25.3M | $20.0K | ||
| Q4 24 | $38.0M | $16.0M | ||
| Q3 24 | $40.4M | $3.0M | ||
| Q2 24 | $37.9M | $3.8M | ||
| Q1 24 | $43.2M | $3.2M |
| Q4 25 | 46.8% | 6.8% | ||
| Q3 25 | 51.4% | 11.0% | ||
| Q2 25 | 49.6% | 10.3% | ||
| Q1 25 | 50.0% | 11.3% | ||
| Q4 24 | 46.5% | 8.9% | ||
| Q3 24 | 53.3% | 12.6% | ||
| Q2 24 | 52.2% | 13.6% | ||
| Q1 24 | 52.4% | 13.0% |
| Q4 25 | 19.4% | -4.1% | ||
| Q3 25 | 13.2% | 0.0% | ||
| Q2 25 | 24.2% | 0.1% | ||
| Q1 25 | 21.9% | 1.2% | ||
| Q4 24 | 24.2% | 19.0% | ||
| Q3 24 | 29.8% | 4.2% | ||
| Q2 24 | 30.3% | 5.0% | ||
| Q1 24 | 27.9% | 4.7% |
| Q4 25 | 13.3% | -3.2% | ||
| Q3 25 | 9.0% | -1.9% | ||
| Q2 25 | 17.8% | -0.8% | ||
| Q1 25 | 14.8% | 0.0% | ||
| Q4 24 | 20.4% | 13.2% | ||
| Q3 24 | 21.1% | 2.2% | ||
| Q2 24 | 20.8% | 2.3% | ||
| Q1 24 | 25.1% | 2.0% |
| Q4 25 | $0.51 | $-0.22 | ||
| Q3 25 | $0.37 | $-0.13 | ||
| Q2 25 | $0.64 | $-0.05 | ||
| Q1 25 | $0.51 | $0.00 | ||
| Q4 24 | $0.74 | $0.76 | ||
| Q3 24 | $0.78 | $0.14 | ||
| Q2 24 | $0.73 | $0.18 | ||
| Q1 24 | $0.81 | $0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $1.5M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $240.7M |
| Total Assets | $1.6B | $563.6M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $1.5M | ||
| Q3 25 | $276.2M | $1.2M | ||
| Q2 25 | $231.8M | $206.0K | ||
| Q1 25 | $236.9M | $183.0K | ||
| Q4 24 | $221.6M | $206.0K | ||
| Q3 24 | $250.5M | $178.0K | ||
| Q2 24 | $217.8M | $314.0K | ||
| Q1 24 | $289.6M | $314.0K |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $240.7M | ||
| Q3 25 | $776.7M | $244.8M | ||
| Q2 25 | $757.5M | $246.8M | ||
| Q1 25 | $751.3M | $250.0M | ||
| Q4 24 | $732.3M | $251.8M | ||
| Q3 24 | $727.7M | $238.4M | ||
| Q2 24 | $713.3M | $238.1M | ||
| Q1 24 | $672.4M | $234.0M |
| Q4 25 | $1.6B | $563.6M | ||
| Q3 25 | $1.7B | $585.6M | ||
| Q2 25 | $1.6B | $433.7M | ||
| Q1 25 | $1.6B | $447.7M | ||
| Q4 24 | $1.6B | $445.6M | ||
| Q3 24 | $1.5B | $466.0M | ||
| Q2 24 | $1.5B | $488.2M | ||
| Q1 24 | $1.6B | $499.9M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $13.4M |
| Free Cash FlowOCF − Capex | $24.6M | $10.2M |
| FCF MarginFCF / Revenue | 13.4% | 7.6% |
| Capex IntensityCapex / Revenue | 4.5% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $26.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $13.4M | ||
| Q3 25 | $52.6M | $1.9M | ||
| Q2 25 | $35.6M | $15.0M | ||
| Q1 25 | $35.1M | $8.3M | ||
| Q4 24 | $29.0M | $38.0M | ||
| Q3 24 | $60.0M | $17.9M | ||
| Q2 24 | $69.1M | $23.3M | ||
| Q1 24 | $55.3M | $10.6M |
| Q4 25 | $24.6M | $10.2M | ||
| Q3 25 | $47.2M | $-1.1M | ||
| Q2 25 | $25.0M | $12.5M | ||
| Q1 25 | $24.4M | $5.4M | ||
| Q4 24 | $16.6M | $35.6M | ||
| Q3 24 | $46.2M | $15.1M | ||
| Q2 24 | $63.1M | $19.2M | ||
| Q1 24 | $46.5M | $7.8M |
| Q4 25 | 13.4% | 7.6% | ||
| Q3 25 | 24.6% | -0.8% | ||
| Q2 25 | 14.3% | 9.5% | ||
| Q1 25 | 14.3% | 4.0% | ||
| Q4 24 | 8.9% | 29.4% | ||
| Q3 24 | 24.1% | 11.1% | ||
| Q2 24 | 34.6% | 11.7% | ||
| Q1 24 | 27.1% | 4.9% |
| Q4 25 | 4.5% | 2.4% | ||
| Q3 25 | 2.8% | 2.1% | ||
| Q2 25 | 6.1% | 1.8% | ||
| Q1 25 | 6.3% | 2.2% | ||
| Q4 24 | 6.7% | 1.9% | ||
| Q3 24 | 7.2% | 2.1% | ||
| Q2 24 | 3.3% | 2.5% | ||
| Q1 24 | 5.1% | 1.7% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | 416.65× | ||
| Q4 24 | 0.76× | 2.38× | ||
| Q3 24 | 1.48× | 6.03× | ||
| Q2 24 | 1.82× | 6.15× | ||
| Q1 24 | 1.28× | 3.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
MEC
| Fabrication | $72.2M | 54% |
| Construction And Access | $19.2M | 14% |
| Tubes | $16.2M | 12% |
| Other Market | $11.9M | 9% |
| Agriculture | $7.7M | 6% |
| Military | $6.7M | 5% |
| Outdoor Sports | $1.7M | 1% |
